Immune to Cancer: The CRI Blog
-
Recapping ASCO20: The Next Horizons in Immunotherapy
The 56th Annual ASCO Meeting highlighted advances in checkpoint immunotherapy, cell-based immunotherapies, and bispecific antibodies.
-
How Immunotherapy Is Transforming Bladder Cancer Treatment
Arjun V. Balar, MD, discusses checkpoint immunotherapy, new FDA approvals, promising new therapies, and clinical trials for…
-
ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy
The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…
-
AACR19 Day 5 Update: Bispecific Antibodies, the Importance of “Helper” T Cells, and the Lloyd J. Old Award Lecture
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to…
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Second Antibody FDA-Approved Against Multiple Myeloma
Elotuzumab (Empliciti) is the second antibody for myeloma approved in just two weeks.
-
Nivolumab Becomes First FDA-Approved Checkpoint Blockade for Kidney Cancer
New hope now exists for patients with advanced kidney cancer.
-
First Monoclonal Antibody for Multiple Myeloma Receives FDA Approval
Daratumumab (Darzalex®) is the first approved immunotherapy that targets CD38—a protein found in most multiple myeloma cells.
-
FDA Approves New Immunotherapy for Leukemia
Amgen’s Blincyto was approved by the FDA, making it the first approved bispecific T cell engaging (BiTE)…